Search results for "agonist"

showing 10 items of 2285 documents

High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.

2015

Naringin is considered the major causative ingredient of the inhibition of intestinal drug uptake by grapefruit juice. Moreover, it is contained in highly dosed nutraceuticals available on the market. A controlled, open, randomized, crossover study was performed in 10 healthy volunteers to investigate the effect of high-dose naringin on the bioavailability of talinolol, a substrate of intestinal organic anion-transporting polypeptide (OATP)-mediated uptake. Following 6-day supplementation with 3 capsules of 350 mg naringin daily, 100mg talinolol were administered orally with 3 capsules of the same dietary supplement (1050 mg naringin) on the seventh day. This test treatment was compared to …

AdultMalefood.ingredientAdrenergic beta-AntagonistsPharmaceutical ScienceOrganic Anion TransportersPharmacologyPolymorphism Single NucleotideDosage formGrapefruit juicePropanolamineschemistry.chemical_compoundFood-Drug InteractionsYoung AdultNutraceuticalfoodPharmacokineticsHumansNaringinDosage FormsCross-Over StudiesDose-Response Relationship DrugChemistryCrossover studyBioavailabilityDietary SupplementsFlavanonesFemaleTalinololCitrus paradisiEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Allelic variants of IL1R1gene associate with severe hand osteoarthritis

2010

Background In search for genes predisposing to osteoarthritis (OA), several genome wide scans have provided evidence for linkage on 2q. In this study we targeted a 470 kb region on 2q11.2 presenting the locus with most evidence for linkage to severe OA of distal interphalangeal joints (DIP) in our genome wide scan families. Methods We genotyped 32 single nucleotide polymorphisms (SNPs) in this 470 kb region comprising six genes belonging to the interleukin 1 superfamily and monitored for association with individual SNPs and SNP haplotypes among severe familial hand OA cases (material extended from our previous linkage study; n = 134), unrelated end-stage bilateral primary knee OA cases (n =…

AdultMalelcsh:Internal medicineLinkage disequilibriumLINKAGE DISEQUILIBRIUMlcsh:QH426-470Hand JointsNF-KAPPA-BSingle-nucleotide polymorphismLocus (genetics)KNEE OSTEOARTHRITISBiologyRADIOGRAPHIC SIGNSPolymorphism Single NucleotideSeverity of Illness IndexGenomeCHROMOSOME 2QINTERLEUKIN-1 RECEPTOR ANTAGONIST03 medical and health sciences0302 clinical medicineOsteoarthritisGeneticsHumansSNPGenetic Predisposition to DiseaseGenetics(clinical)Allelelcsh:RC31-1245GeneAllelesPOLYMORPHISMSGenetics (clinical)AgedHAPLOTYPE RECONSTRUCTION030304 developmental biologyReceptors Interleukin-1 Type I030203 arthritis & rheumatologyGenetics0303 health sciencesHaplotypeCLUSTERMiddle Aged314 Health sciences3. Good healthlcsh:GeneticsCase-Control StudiesDISC DEGENERATIONFemaleResearch ArticleBMC Medical Genetics
researchProduct

Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.

2018

Aims Aim of this study was to associate concentration of naltrexone and its major active metabolite 6β-naltrexol in blood with therapeutic outcome during treatment with naltrexone in subjects with alcohol dependence. Treatment with the μ-opiate receptor antagonist naltrexone has been shown to reduce craving for alcohol and alcohol intake in patients suffering from alcohol dependence. Short summary This article shows the use of therapeutic drug monitoring in alcohol dependent patients, who are treated with naltrexone. The plasma concentrations of naltrexone and 6β-naltrexol showed high inter-individual variability. They were predictive for treatment response, as they correlated significantly…

AdultMalemedicine.drug_classAcamprosateNarcotic Antagonists030508 substance abuseCravingAlcoholPharmacologyNaltrexone03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodReference ValuesmedicineHumansActive metaboliteCravingEthanolmedicine.diagnostic_testbusiness.industryAlcohol dependenceGeneral MedicineMiddle AgedReceptor antagonistNaltrexoneAlcoholismTreatment OutcomechemistryTherapeutic drug monitoringDrug Therapy CombinationFemalemedicine.symptomDrug Monitoring0305 other medical sciencebusiness030217 neurology & neurosurgerymedicine.drugAlcohol DeterrentsAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

Urine tropenol ester levels in workers handling tiotropium bromide synthesis: implications for exposure prevention and biomonitoring

2019

Tropenol ester is a highly toxic anticholinergic substance and an intermediate used in industrial production of the bronchodilator tiotropium bromide. The aim of this study was to systematically test workers involved in its production for tropenol ester in urine to identify any exposure pathways and define additional preventive measures. Twelve workers performing tasks involving potential exposure to tropenol ester were repeatedly monitored at the end of each production cycle. Medical exams revealed no symptoms of acute poisoning with tropenol ester, but biological monitoring of urine showed 36 positive findings in 79 samples, with tropenol ester concentrations ranging between the detection…

AdultMalemedicine.drug_classProduction cycleAnticholinergic agentsUrinePharmacologyToxicologyCholinergic AntagonistsYoung Adult03 medical and health sciences0302 clinical medicineOccupational ExposureBronchodilatorBiomonitoringAnticholinergicmedicineHumans030212 general & internal medicineTiotropium Bromidebusiness.industryanaliza radnog mjesta; antikolinergici; međuproizvodi; prevencija; skopin esterPublic Health Environmental and Occupational Healthanticholinergic agents; intermediates; prevention; scopine ester; workplace analysisTiotropium bromide030210 environmental & occupational healthAcute toxicitybusinessBiological MonitoringEnvironmental Monitoringmedicine.drugArchives of Industrial Hygiene and Toxicology
researchProduct

Influence of low temperature on bronchodilatation induced by terbutaline administered by metered dose or dry powder inhalers in asthmatics.

2000

Low temperatures may affect dose delivery efficacy and clinical effectiveness of medication aerosols. In this study we examine the effect of cold ambient temperature on the bronchodilatation produced by terbutaline delivered from a chlorofluorocarbon pressurized metered dose inhaler (pMDI) compared to a multi-dose dry powder inhaler (DPI). Fourteen stable asthmatics were studied on two consecutive days. On day 1, after measuring FEV1 at room temperature (22 degrees C), each patient was randomized to receive 500 microg of terbutaline delivered from pMDI or DPI stored for 24 h at 22 degrees C with FEV1 recorded 20 min post-dose; then, patients were placed in a chamber at -10 degrees C, and af…

AdultMalemedicine.drug_classTerbutalineCold storageBronchiBronchodilatorForced Expiratory VolumeAdministration InhalationmedicineTerbutalineHumansPharmacology (medical)PharmacologyDose-Response Relationship DrugCumulative doseChemistryInhalerAdrenergic beta-AgonistsMiddle AgedMetered-dose inhalerDry-powder inhalerAsthmaBronchodilator AgentsCold TemperatureBronchodilatationAnesthesiaFemalePowdersmedicine.drugFundamentalclinical pharmacology
researchProduct

Blockade of nicotinic and muscarinic receptors facilitates spontaneous migration of human peripheral granulocytes: failure in cystic fibrosis.

2012

Circulating leucocytes express muscarinic (m) and nicotinic (n) receptors and synthesize acetylcholine (ACh) regulating various cell functions. Leucocytes from patients with cystic fibrosis contain less ACh; therefore it was tested whether the regulation of cellular functions like migration differed from healthy volunteers.Peripheral blood (10-20 ml) was used, leucocytes were isolated by Ficoll® gradient and the commercial MIGRATEST® combined with flow cytometric analysis was applied (pore size 3 μm).In the absence of test substances 4900±1800 (n=10) leucocytes migrated within a time period of 2 h. In the presence of tubocurarine (TC, 30 μM) the cell number increased to 7500±2700 [n=10] cor…

AdultMalemedicine.medical_specialtyAdolescentCystic FibrosisBiologyReceptors NicotinicGeneral Biochemistry Genetics and Molecular BiologyCholinergic AntagonistsYoung AdultCell Migration Assays LeukocyteCell MovementInternal medicineMuscarinic acetylcholine receptormedicineMuscarinic acetylcholine receptor M4HumansGeneral Pharmacology Toxicology and PharmaceuticsReceptorChildMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2General MedicineReceptors MuscarinicNicotinic agonistEndocrinologyCholinergicFemaleAcetylcholinemedicine.drugGranulocytesLife sciences
researchProduct

Dose-Related Effects of Amisulpride on Five Dimensions of Psychopathology in Patients With Acute Exacerbation of Schizophrenia

2002

The present analysis investigated symptom-specific dose-response relationships of the atypical antipsychotic amisulpride (AMI) in schizophrenic patients. The effects of different AMI doses on five different symptom dimensions of the Brief Psychiatric Rating Scale (BPRS) were analyzed. Results on global efficacy and safety parameters have been previously published. Four AMI doses (100 mg/day [AMI100], 400 mg/day [AMI400], 800 mg/day [AMI800], 1200 mg/day) were compared with 16 mg haloperidol (HAL16) in a multicenter, double-blind, randomized, parallel-group, 4-week trial. A total of 319 patients with acute exacerbation of schizophrenia (DSM-III-R) were included. AMI100 was compared with the …

AdultMalemedicine.medical_specialtyAdolescentExacerbationmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticInternal medicineBrief Psychiatric Rating ScalemedicineHaloperidolHumansPharmacology (medical)AmisulpridePsychiatryAntipsychoticPsychiatric Status Rating ScalesDose-Response Relationship DrugDopamine antagonistMiddle AgedPsychiatry and Mental healthTreatment OutcomeSchizophreniaHaloperidolAnxietyFemaleSchizophrenic PsychologyAmisulprideSulpiridemedicine.symptomPsychologyAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Increased sensitivity of the neuronal nicotinic receptor alpha-2 subunit causes familial epilepsy with nocturnal wandering and ictal fear

2006

Sleep has traditionally been recognized as a precipitating factor for some forms of epilepsy, although differential diagnosis between some seizure types and parasomnias may be difficult. Autosomal dominant frontal lobe epilepsy is characterized by nocturnal seizures with hyperkinetic automatisms and poorly organized stereotyped movements and has been associated with mutations of the α4 and β2 subunits of the neuronal nicotinic acetylcholine receptor. We performed a clinical and molecular genetic study of a large pedigree segregating sleep-related epilepsy in which seizures are associated with fear sensation, tongue movements, and nocturnal wandering, closely resembling nightmares and sleep …

AdultMalemedicine.medical_specialtyAdolescentSomnambulismMolecular Sequence DataMutation MissenseAutosomal dominant nocturnal frontal lobe epilepsyReceptors NicotinicBiologymedicine.disease_causeLigandsNicotinicArticleEpilepsyBIO/09 - FISIOLOGIAInternal medicineAcetylcholine; Adolescent; Adult; Aged; Aged 80 and over; Amino Acid Sequence; Epilepsy; Female; Humans; Ligands; Male; Molecular Sequence Data; Mutation Missense; Neurons; Pedigree; Receptors Nicotinic; Somnambulism; FearReceptorsmedicine80 and overGeneticsHumansIctalGenetics(clinical)Amino Acid SequenceGenetics (clinical)Acetylcholine receptorAgedAged 80 and overNeuronsMutationEpilepsySeizure typesFearmedicine.diseaseAcetylcholinePedigreeNicotinic acetylcholine receptorNicotinic agonistEndocrinologyMutationnAChR patch-clamp ADNFLE sleep-related epilepsy M1 TM1 ACh nicotineSettore MED/26 - NeurologiaFemaleMissense
researchProduct

Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled …

2016

Background Chronic spontaneous urticaria (CSU) severely impacts quality of life (QoL), especially in patients with wheals and angioedema. Omalizumab is approved as add-on therapy for CSU patients; however, its effect on patients who are double-positive for wheals and angioedema has not been systematically studied. Objective The primary objective was to evaluate the efficacy of omalizumab vs placebo at week 28 using the Chronic Urticaria Quality of Life (CU-Q2oL) questionnaire. Number of angioedema-burdened days, time interval between successive angioedema episodes, disease activity, angioedema-specific and overall QoL impairment were secondary objectives. Methods X-ACT was a phase III, rand…

AdultMalemedicine.medical_specialtyAdolescentUrticariamedicine.medical_treatmentImmunologyDrug ResistanceOmalizumabOmalizumabPlacebolaw.inventionYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifeimmune system diseaseslawInternal medicineAnti-Allergic AgentsmedicineHumansImmunology and AllergyAngioedemaYoung adultskin and connective tissue diseasesAdverse effectAgedAngioedemabusiness.industryMiddle AgedTreatment Outcome030228 respiratory systemAnesthesiaChronic DiseaseRetreatmentHistamine H1 AntagonistsQuality of LifeFemaleAntihistaminemedicine.symptombusinessmedicine.drugAllergy
researchProduct

Incidence of postoperative nausea and vomiting (PONV) after general pre-anaesthetic prophylaxis with antihistamines

2004

AdultMalemedicine.medical_specialtyAllergyNeurologyVomitingAnesthetics GeneralImmunologyPharmacology toxicologyConscious SedationInternal medicinemedicineHumansAgedPharmacologybusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseaseRheumatologyAnesthesiaPostoperative Nausea and VomitingHistamine H1 AntagonistsFemalemedicine.symptombusinessPostoperative nausea and vomitingInflammation Research
researchProduct